Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ:CDMO) will report its financial results for the quarter and fiscal year ending April 30, 2021, on June 29, 2021, after market close. A conference call will be held at 1:30 PM PT (4:30 PM ET) to discuss these results and recent corporate developments. Avid is a contract development and manufacturing organization that specializes in biopharmaceutical drug manufacturing and offers a range of services including process development and regulatory support. Following 28 years of experience in the industry, Avid aims to enhance patient outcomes through quality services.

Positive

• Avid has 28 years of experience producing monoclonal antibodies and recombinant proteins.
• The company offers comprehensive services including CGMP clinical and commercial manufacturing.

Negative

• None.

TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2021 on June 29, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2021 and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

FAQ

When will Avid Bioservices announce its financial results for FY 2021?

Avid Bioservices will announce its financial results for the fiscal year ended April 30, 2021, on June 29, 2021.

What time is the Avid Bioservices conference call scheduled for?

The conference call to discuss Avid Bioservices' financial results is scheduled for 1:30 PM Pacific Time (4:30 PM Eastern Time) on June 29, 2021.

What services does Avid Bioservices provide?

Avid Bioservices specializes in contract development and manufacturing for biopharmaceuticals, including CGMP clinical and commercial manufacturing, process development, and regulatory submissions support.

What is the stock symbol for Avid Bioservices?

The stock symbol for Avid Bioservices is CDMO.